Cerebral Therapeutics is a clinical-stage pharmaceutical company dedicated to improving the lives of patients living with uncontrolled neurological diseases, beginning with refractory epilepsy.
Information on this site is intended for informational purposes only and is not medical advice.
Our platform is designed to deliver therapy where it’s needed most, while minimizing systemic exposure.
Illustration only, not actual clinical data.
Traditional systemic therapies can struggle to achieve the right exposure in the brain while avoiding unwanted side effects elsewhere in the body. Cerebral Therapeutics is developing a platform designed to deliver therapy directly to the central nervous system, with the goal of improving control of severe neurologic conditions.
Our initial focus is on patients whose seizures remain uncontrolled despite currently available anti-seizure medications. Many of these individuals live with persistent seizures and a significant burden on quality of life.
Cerebral Therapeutics is a clinical-stage company. Any potential therapies described are investigational and have not been approved for commercial use.
Cerebral Therapeutics is advancing investigational therapies through clinical development with the goal of offering new options to patients living with refractory neurologic disease.
Our lead investigational program is focused on individuals with epilepsy who continue to experience seizures despite standard therapies. The program is based on our direct-to-brain delivery platform.
Development status: Clinical-stage
Over time, the platform may be evaluated in additional severe neurologic disorders where direct CNS delivery could offer a meaningful advantage over systemic approaches.
Any potential future indications are subject to additional research, regulatory review and clinical investigation.
For more information about Cerebral Therapeutics, you can also visit our company profile on Crunchbase.
Cerebral Therapeutics is a clinical-stage pharmaceutical company dedicated to patients whose neurological conditions remain uncontrolled despite current treatment options. By integrating innovative drug delivery, neurology and pharmaceutical development, we are working to bring new therapeutic possibilities directly to the brain.
Our team brings together experience across neurology, drug development, clinical research, engineering and regulatory strategy, all focused on a single goal: to make a meaningful difference for patients and the people who care for them.
We work with investigators, clinicians, research centers and advocacy groups to better understand the needs of patients living with uncontrolled neurologic disease and to design clinical programs aligned with those needs.
If you or a loved one lives with refractory epilepsy or another uncontrolled neurologic condition, it can be difficult to find options that offer better control. Cerebral Therapeutics is developing investigational therapies that are being evaluated in clinical studies.
If you are interested in learning more about our investigational programs, please ask your healthcare provider to contact us through this site.
We welcome conversations with neurologists, epileptologists, neurosurgeons, research centers and potential collaborators interested in our direct-to-brain platform and clinical programs.
Please use the contact form below to reach our team for more information on collaboration.
Responses below are for general information only, are subject to change, and are not a substitute for advice from a qualified healthcare professional.
We understand that patients, families and clinicians may have questions about our approach, investigational therapies and how to connect with our team. These FAQs provide a starting point.
For questions specific to your health or treatment, always speak with your healthcare provider.
No. Cerebral Therapeutics is a clinical-stage company. Our programs are investigational and are being evaluated in clinical studies. They have not been approved by regulatory authorities for general use.
In general terms, direct-to-brain or direct-to-CNS delivery refers to approaches that deliver therapy closer to the central nervous system, with the goal of achieving targeted exposure in the brain while minimizing systemic exposure. Specific details vary by program and device design.
Information about clinical trials is typically available through public clinical trial registries and from participating research centers. Your healthcare provider is the best person to discuss whether a clinical trial may be appropriate for you.
No. The content of this website is for informational purposes only and does not constitute medical advice, diagnosis or treatment recommendations. Always speak with your healthcare provider about your specific medical condition and any treatment decisions.
If you are a clinician, researcher, potential collaborator, or if you have general inquiries about Cerebral Therapeutics, please contact us using the details below or the form on this page.
Address:
3510 Hopkins Place North, Building 4, Suite 233A
Oakdale, MN 55128
United States
Email: info@cerebraltherapeutics.store
Phone: +1 (303) 547-3448
Please do not include personal medical information in this form. For questions about your health or treatment, contact your healthcare provider directly.
Cerebral Therapeutics respects the privacy of visitors to this website. We may collect limited information such as contact details when you voluntarily submit them to us, for example through an inquiry form or email. This information is used to respond to your request and to operate and improve our communications.
We do not sell your personal information. In certain cases, information may be shared with service providers or partners who assist us in operating the website or responding to your inquiry, under appropriate safeguards.
Because Cerebral Therapeutics is a clinical-stage company, information about clinical research is governed by additional regulations and processes. If you participate in a clinical study, the handling of your data is described in the study’s informed consent documents.
If you have questions about this Privacy Policy, please contact us at info@cerebraltherapeutics.store.
By accessing this website, you agree to use it for lawful purposes and in a manner that does not infringe on the rights of Cerebral Therapeutics or any third party. The content provided is for general informational purposes only and does not constitute medical advice, diagnosis or treatment.
While we endeavor to keep the information on this site accurate and up to date, we make no warranties or representations about its completeness or suitability for any particular purpose. Cerebral Therapeutics reserves the right to modify, update or remove website content at any time.
All trademarks, logos, graphics and text on this site are the property of Cerebral Therapeutics or its licensors and may not be used without prior written permission.